‘Why Biology Is Not Destiny’: An Exchange
By Kathryn Paige Harden et al.,
The New York Review
| 05. 25. 2022
Kathryn Paige Harden, Nick Patterson, Victor I. Reus, and Henry D. Schlinger Jr., reply by M.W. Feldman and Jessica Riskin
In response to:
Why Biology Is Not Destiny from the April 21, 2022 issue
To the Editors:
Marcus Feldman and Jessica Riskin did not like my book. Or rather, they did not like a book called The Genetic Lottery by an author named “Kathryn Paige Harden,” but their review [NYR, April 21] so badly distorts my arguments that I have the curious impression that Feldman and Riskin somehow got their hands on another book entirely, an evil doppelgänger to mine. Therapists, parents, and the unhappily married would recognize the feeling I had upon reading their review the first time: it’s both vexing and bewildering when someone is spoiling for a fight about something you never said.
As a longtime reader of The New York Review of Books, I am surprised and disappointed that this review was published in such an esteemed outlet. Yes, “we all enjoy an intemperate paragraph of syntactically inspired bile,” to quote Zadie Smith, and Feldman and Riskin do deliver the bile. But I assume that, besides wanting to be entertained by vitriol...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...